Product Description
For Chronic Obstructive Pulmonary Disease
Mechanisms of Action: M3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chiesi
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Asthma|Chronic Obstructive Pulmonary Disease
Phase 1: Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2019-002238-35 | P2 |
Completed |
Asthma |
2021-02-04 |
|
GLIMMER | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2018-05-23 |
73% |
2015-000558-40 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2017-02-06 |
|
GlycoNEXT | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2017-02-06 |
|
CCD-06302AA1-02 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2016-08-01 |
|
ELITRA | P2 |
Completed |
Asthma |
2015-08-13 |
|
ELITRA | P2 |
Completed |
Asthma |
2015-08-01 |
|
TRISKEL | P2 |
Completed |
Asthma |
2015-03-08 |
|
Triskel | P2 |
Completed |
Asthma |
2015-03-01 |
|
2013-005268-25 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2015-02-06 |
|
Trigon | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2015-02-01 |